Persistent luminescence nanoparticles for cancer theranostics application

Table 3 A summary of published works about PLNPs-based chemotherapy

PLNPs	Surface coating	Loaded drug	Loading capacity	Operated subject	Refs.
Hollow ZnGa₂O₄:Cr	BSA	DOX	181 mg/g	Animal (iv)	[54]
Mesoporous Zn_1.07Ga_2.34Si_0.98O_6.56:Cr_0.01	BSA	DOX	62 wt %	Animal (iv)	[66]
Zn_1.1Ga_1.8Ge_0.1O₄:Cr³⁺	Mesoporous silica	DOX	4.5 wt%	cells	[32]
Gd₃Ga₅O₁₂:Cr³⁺, Nd³⁺	Mesoporous Silica	DOX	8.5 wt%	Animal (it)	[34]
ZnGa₂O₄:Cr³⁺,Sn⁴⁺	Mesoporous Silica	Paclitaxel	187 mg/g	cells	[126]
ZnGa₂O₄:Cr³⁺,Sn⁴⁺	Mesoporous Silica	Afatinib	15 wt%	Animal (iv)	[120]
Zn_1.25Ga_1.5Ge_0.25O₄: Cr³⁺, Yb³⁺, Er³⁺	Mesoporous Silica, RBC vesicles	DOX	7.1 ± 0.3 wt%	Animal (iv)	[70]
Zn_1.25Ga_1.5Ge_0.25O₄: Cr³⁺, Yb³⁺, Er³⁺	Mesoporous Silica, Lactobacillus reuteri biofilm	Fluorouracil	8.5 wt%	Animal (it)	[73]
Zn_1.1Ga_1.8Ge_0.1O₄:Cr³⁺,Eu³⁺	Mesoporous silica	DOX	105.9 mg/g	Animal (iv)	[121]
Zn_1.1Ga_1.8Ge_0.1O₄:Cr³⁺	Liposome	Paclitaxel	69.2 ± 2.8 wt%	Animal (iv)	[122]
Zn_xGa_yGe_zO₄:Cr³⁺	ZIF-8	DOX	93.2 wt%	Animal (it)	[125]
ZnGa₂O₄:Cr³⁺	ZIF-8	DOX	90 wt%	Animal (iv)	[124]

ISSN: 1477-3155